The Peptide That Cuts Heart Attacks and Deaths: Separating Science From Hype

Gil Carvalho
Gil Carvalho
Nov 14, 2026 • 12 min read

One peptide has reduced the combined risk of heart attacks, strokes, and cardiovascular deaths by 20% in a large human trial. Another is being injected into people on the strength of three uncontrolled studies involving just 30 patients.

Both are called peptides. That is about where the similarity ends.

Some peptides are genuine medical breakthroughs. Others are marketed for tissue repair, muscle growth, hair restoration, and anti-aging with promises that run far ahead of the evidence. The useful question is not whether peptides are good or bad. It is which peptide, for which condition, supported by what human research?

I have no peptides, supplements, or prescription drugs to sell. What interests me is the gap between what the science shows and what people are being told.

Key Takeaways

  • Semaglutide has strong human trial evidence, including reduced cardiovascular events in a defined population.
  • Many peptides marketed for healing, muscle growth, and anti-aging lack convincing controlled human evidence.
  • Results from related molecules or topical treatments do not validate a different peptide or injection.
  • Permission to sell an experimental peptide is not the same as FDA approval.

Table of Contents

What Is a Peptide?

A peptide is a short chain of amino acids, essentially a small piece of a protein. When you eat protein, your digestive system breaks it into peptides and then into individual amino acids.

But peptides are not just products of digestion. Some function as chemical messengers.

Insulin is a familiar example. It is both a hormone and a peptide. It travels through the bloodstream and binds to a specific receptor, rather like a key fitting a lock, helping regulate metabolism.

That ability to interact with biological targets makes certain peptides useful medicines. It does not make every peptide effective, and it certainly does not make every peptide safe. Each compound needs its own evidence.

Semaglutide, widely recognized by the brand name Ozempic, activates the GLP-1 receptor. Its effects in the brain, gut, and other tissues reduce appetite and food cravings.

Related drugs activate additional pathways. Tirzepatide targets two receptors, while the investigational drug retatrutide targets three. Retatrutide had not been approved at the time of this assessment.

The weight-loss results from the trials discussed are substantial:

  • Semaglutide: approximately 15% of initial body weight.
  • Tirzepatide: approximately 21%.
  • Retatrutide: approximately 24%.

These are approximate results from different trials, not a guarantee for an individual or a direct comparison under identical conditions. The relevant studies include trials of semaglutide for weight management, tirzepatide for obesity, and retatrutide for obesity.

Benefits beyond weight loss

The most fascinating part is that the benefits are not limited to the number on the scale.

In the SELECT cardiovascular outcomes trial, semaglutide reduced the combined risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20% relative to placebo in the population studied. All-cause mortality, meaning death from any cause, was also lower by approximately 19%.

That distinction matters: the 20% figure refers to a combined outcome and a relative reduction, not a 20-percentage-point reduction in everyone's risk.

Across trials of this family of medicines, researchers have also found benefits involving:

  • Prevention of progression to type 2 diabetes.
  • Kidney protection.
  • Improvement in fatty liver disease.
  • Reduced knee osteoarthritis pain.
  • Improvement in obstructive sleep apnea.
  • Fewer heavy drinking days in preliminary research involving people with alcohol use disorder.

These findings do not mean every drug in the family has proved every benefit. The drug, dose, condition, and population matter. But these are findings from randomized human trials, generally with placebo controls and double blinding. The broader research program includes thousands of participants.

Keep that standard of evidence in mind. It becomes important when we get to the peptides advertised on social media.

The limitations and side effects are real, too

These treatments are not magic, and they are not free of trade-offs.

Some of the weight lost is lean mass, approximately one-quarter to one-third in the estimates discussed. Lean mass is not all muscle, although some of it is. Muscle loss can accompany weight loss through other methods as well, particularly when muscles are not being challenged.

Resistance training and adequate protein intake are important ways to help minimize muscle loss during weight reduction.

Common adverse effects include nausea, vomiting, diarrhea, and constipation. And semaglutide is not a permanent cure for appetite or weight regulation. Its half-life is roughly a week. When treatment stops and its effects fade, cravings can return, and weight regain is common.

Another open question is how much of the health benefit comes directly from weight loss. The trials discussed largely involved people with overweight or obesity, but growing evidence suggests that at least some effects may not be fully explained by changes in body weight. That remains an active area of research.

Other established peptide medicines

GLP-1 medicines are not the only peptides with legitimate clinical uses:

  • Insulin has been used for decades to treat diabetes.
  • Teriparatide is an established osteoporosis treatment.
  • Tesamorelin has an established role in HIV-associated lipodystrophy.

So the position here is not “peptides do not work.” Some clearly do. The problem is treating the word peptide as though it were itself a stamp of medical validation.

BPC-157: The “Wolverine Peptide” Has Very Little Human Evidence

BPC-157 is probably the best-known experimental peptide marketed for tissue healing. The name sounds like a Wi-Fi password, but BPC stands for “body protection compound.” It contains 15 amino acids and is produced synthetically from a sequence associated with a protein found in the gut.

In laboratory animals, the results are interesting. Studies suggest effects on the healing of tendons, ligaments, muscle, bone, and the gut lining.

In humans, the evidence is a very different story.

The published evidence reviewed consisted of three studies totaling 30 people, with no control group in any of them.

What the three studies actually tell us

In a study of BPC-157 injections for knee pain, 16 patients received injections into the knee. Researchers later contacted them, and most reported substantial improvement.

Interesting? Yes. Proof that the peptide worked? No.

Without a comparison group, we cannot tell whether the improvement reflected the treatment, natural recovery, expectations, or something else. We cannot even exclude the possibility that recovery would have been faster without it.

A second study involved 12 women with bladder pain who received BPC-157 directly into the bladder. Follow-up reports suggested considerable improvement, with many reporting complete pain relief. Again, there was no control group, and the finding had not been independently repeated.

The third study examined intravenous administration in just two people. They were followed for 72 hours. Neither reported side effects, and their blood work did not change over those three days.

That is the entirety of the intravenous human evidence discussed: two people, three days. It cannot establish long-term safety or detect uncommon adverse effects.

There is also a record of an older randomized trial, described in a 2005 conference abstract, involving inflammatory bowel symptoms. The full study was never published in a medical journal. It also used rectal administration as an enema, not the injections commonly promoted online.

A systematic review of the human evidence concluded that BPC-157 should not be used clinically outside clinical trials. We do not yet have convincing evidence of safety, let alone reliable evidence of benefit.

Why widespread clinical use is so troubling

Celebrity endorsements and affiliate codes are predictable. More concerning is the willingness of some health professionals to treat this as routine medicine.

On Andrew Huberman's podcast, a family physician described using BPC-157 with almost every patient, choosing initial doses based on animal studies, and administering it intravenously for injuries.

That is not a description of a carefully monitored trial. Nor is it a difficult individual case in which established options have failed and an experimental approach is being considered. It is broad use of an inadequately studied treatment.

I find that scientifically and medically indefensible. A confident explanation from a doctor does not substitute for controlled human evidence.

Positive and Negative Anecdotes Have the Same Problem

Online accounts of BPC-157 include people saying their pain disappeared and others describing panic attacks, altered vision, brain fog, fatigue, anxiety, or twitching.

News reporting has described a weightlifter who developed persistent symptoms after taking the peptide. Adverse-event reports submitted to the FDA have also included hospitalizations, including one described as life-threatening.

Those reports deserve attention. They do not, by themselves, prove that BPC-157 caused the problems.

The same caution applies to success stories. Several explanations can complicate both kinds of anecdote:

  • Expectations: placebo effects can substantially change how symptoms feel.
  • Natural recovery: pain and injuries can improve over time without the treatment.
  • Contamination: gray-market products may contain substances other than the intended peptide.
  • Unrelated events: a health change after an injection may have another cause.

Some products are sold in vials labeled for research use only or not for human consumption. That label is not evidence that injecting the contents is safe.

Anecdotes have more holes than Swiss cheese. That is why we need controlled studies before turning an experimental compound into a routine injection.

TB-500: Research on a Whole Protein Does Not Validate a Fragment

TB-500 is another peptide marketed for tissue repair. Combined with BPC-157, it is sometimes sold as the “Wolverine Stack.” The name is memorable. The human evidence is missing.

The key distinction is between TB-500, discussed here as a seven-amino-acid fragment, and the full 43-amino-acid protein thymosin beta-4.

There is human research on the full protein. It includes research involving dry-eye treatment, along with preliminary work on wound healing and recovery of heart muscle after a heart attack.

But those findings cannot simply be transferred to an isolated fragment.

A small section of a protein, manufactured and injected separately, may not behave like the whole molecule. For the TB-500 fragment discussed here, there were no published human studies in the evidence reviewed.

Evidence for a related molecule is not evidence for the product being sold.

Angiogenesis: a reason to investigate safety, not declare cancer risk proved

Laboratory research suggests that BPC-157 and TB-500 can promote the growth of new blood vessels, a process called angiogenesis.

That could help explain some of the tissue-repair findings in animals. More blood supply can support healing.

But angiogenesis also matters in tumor growth. Tumors need a blood supply, and some cancer treatments work by interfering with that supply.

This does not establish that these peptides cause cancer. It establishes a reasonable safety question that needs proper investigation.

The distinction is essential. “We do not know whether this creates a problem” is not the same as “this definitely creates a problem.” It is also not the same as “this is safe.”

GHK-Cu for Skin and Hair: Promising, but the Claims Need Boundaries

GHK-Cu contains three amino acids bound to copper. Among the experimental peptides discussed, it has a more promising human evidence base, including some randomized trials.

Still, the results are preliminary and mixed. Importantly, the studies generally used topical creams or serums, not injections.

  • Leg and foot ulcers: two trials produced inconsistent findings, with one reporting improvement and another not finding a benefit.
  • Facial skin: some studies suggest improvements in wrinkles, but results do not all agree.
  • Eyebrow hair: one study reported increases in hair number and thickness.

The broader research on GHK and its copper complex is biologically interesting. But the marketing often skips the boundaries of what was tested.

Eyebrow results do not establish scalp-hair regrowth. Topical results do not establish the safety or effectiveness of injections. In the evidence reviewed, human scalp-hair benefits had not been demonstrated.

If you are paying for GHK-Cu to restore your hairline, that gap matters.

Epitalon: Telomere Findings Are Not Proof of Anti-Aging

Epitalon, also spelled epithalon, is marketed as an anti-aging peptide.

In isolated cells, it has shown effects related to telomeres, the protective ends of chromosomes that can shorten with age. Animal studies, including experiments in fruit flies, have reported modest lifespan extensions of roughly 10% to 15%.

That sounds impressive until you put it in context. During my PhD, I ran lifespan experiments in fruit flies and other laboratory animals. Many interventions can extend lifespan by that amount in those systems. A great many do not translate into useful human treatments.

The human research discussed includes effects on melatonin levels in older people and a small, poorly controlled study involving retinitis pigmentosa, a genetic eye disease.

Those are research leads, not demonstrations of longer life or meaningful age reversal.

Another limitation is that almost all the research comes from the same Russian research group, with little independent validation.

There is no convincing human evidence here that epitalon extends lifespan or reverses aging. Selling it as an established anti-aging treatment turns a laboratory hypothesis into a marketing claim.

Ipamorelin and CJC-1295: Higher Hormone Levels Do Not Prove Bigger Muscles

Ipamorelin and CJC-1295 are popular in bodybuilding and biohacking circles. Both can stimulate growth hormone release in humans. CJC-1295 can also raise IGF-1, a growth factor, as shown in human research measuring its hormonal effects.

But raising a hormone is not the same as demonstrating a useful clinical result.

The evidence discussed did not establish that these peptides increase muscle size, improve strength, or deliver the recovery benefits used to market them.

There are safety questions, too. Growth hormone and IGF-1 participate in pathways involved in tumor growth. That does not prove these injections cause cancer, but it is another reason long-term safety research is necessary.

A change in a blood test is a biological effect. It is not automatically a health benefit.

FDA Peptide Policy: Permission to Sell Is Not Approval

The regulatory story makes all of this more confusing. Headlines about wider access can easily sound like announcements that experimental peptides have been approved.

An advisory committee vote, a policy allowing sales, and FDA drug approval are different things.

In the policy developments examined here, FDA scientists reviewed experimental peptides and identified insufficient evidence of clinical benefit, along with potential concerns including liver damage and allergic reactions.

An advisory committee was then scheduled to consider restrictions. Before the vote, Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly supported peptides and described using them himself, brought eight new members onto a committee that already had seven.

The reported additions included six people involved in peptide sales, a compounding pharmacist, and a pharmacy business executive. Those are significant conflicts to consider when the decision affects the market for compounded peptides.

The eight new members voted to reduce restrictions on six experimental peptides, including TB-500. A dissenting liver specialist raised an important point: problems such as liver injury or cancer may take years to become apparent.

What the vote did and did not establish

The July committee vote described in this assessment was advisory. It did not constitute FDA approval.

Kennedy subsequently announced a policy intended to permit broader sales before the full regulatory process had concluded. That announcement was not new clinical evidence. It did not resolve the unanswered questions about effectiveness or long-term safety.

These regulatory details are time-sensitive, but the underlying distinction is durable: availability does not establish that a treatment has been proved safe and effective.

Conflicts of interest should matter consistently

My concern is not which industry benefits or which political party is involved. People with direct commercial stakes should not be positioned to determine the market access of the products they sell.

Complaining about industry influence while appointing people with financial ties is not a solution. The same concern applies to food-industry influence in dietary guidance, whether the beneficiaries are beef and dairy businesses or anyone else.

There is also an obvious inconsistency in demanding ever more testing for vaccines while embracing peptides with barely any human evidence. The evidentiary standard should not change according to personal enthusiasm.

Health agencies should make decisions from scientific evidence, not feelings, internet stories, or commercial preferences.

Personal Freedom Does Not Excuse Misleading Medicine

There is a reasonable debate about whether people already purchasing gray-market peptides would be better served by a cleaner, more reliable supply.

But product purity and clinical effectiveness are separate questions. A cleaner vial does not tell us whether the molecule helps, what dose is appropriate, or what happens after years of use.

I support personal freedom. People can make decisions about their own bodies. What I oppose is indiscriminate, for-profit administration of experimental treatments while scientific language and confident promises leave patients believing the uncertainty has already been resolved.

There is another possible consequence: allowing broad sales without evidence could weaken the incentive to conduct proper trials. If a company can already profit, why invest millions to find out whether the product works?

That would leave everyone stuck with the same anecdotes and unanswered questions.

The Question to Ask Before Accepting a Peptide Treatment

Inflammation, telomeres, tissue repair, growth factors. These terms can sound impressive. None answers the question that matters most: does the treatment actually improve a meaningful outcome in humans?

Before accepting a peptide treatment, ask:

Has this specific peptide, given by this route for this purpose, been tested in a controlled human trial?

Not a related protein. Not rats. Not cells in a dish. Not “my patients love it.” Actual evidence.

Then ask what is known about safety, how long participants were followed, and whether the person recommending it also profits from selling it.

Some peptides deserve their place in medicine. Others deserve further research. Those are very different categories, and patients deserve to know which one they are being offered.

This information is educational and is not a substitute for individualized medical advice. Discuss treatment decisions with a qualified healthcare professional.

Share

Nutrition Made Simple!

We break down nutrition and health research into practical food choices, clear explanations and evidence-based fact-checks.

© 2026 Nutrition Made Simple!
Powered by Convella